Forest Laboratories
http://www.frx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Forest Laboratories
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
FTC’s Salvos Against Biopharma To Reverberate Through 2024
The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.
FTC/Industry Showdown Over Orange Book Patent Listings Could Come In 2024
GlaxoSmithKline, Amneal and Kaleo delist patents on inhalers and autoinjectors in drug-device combination products in response to FTC criticism. But AstraZeneca, Boehringer Ingelheim, and Teva hold firm, teeing up legal battles if the Commission takes enforcement action.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Company Information
- Other Names / Subsidiaries
-
- Actavis, Cerexa Inc., Clinical Data Inc., Forest Healthcare B.V., Forest Laboratories Holdings Ltd, Forest Laboratories Ireland Ltd, Forest Laboratories UK Ltd, Forest Pharmaceuticals, Forest Research Institute Inc, Forest Tosara Ltd, Inwood Laboratories
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice